PROWESS

PROWESS
Name	PROWESS
Full name	PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis)
Type	Randomized controlled trial
Intervention	Drotrecogin alfa (activated) [recombinant human activated protein C]
Condition	Severe sepsis, septic shock
Sponsor	Eli Lilly and Company
Start date	1999
Publication	2001 (New England Journal of Medicine)

PROWESS PROWESS was a pivotal multicenter randomized clinical trial that evaluated drotrecogin alfa (activated) for adults with severe sepsis and high risk of death. Launched near the turn of the 21st century, the trial influenced guidelines from organizations such as the Surviving Sepsis Campaign, shaped regulatory decisions by agencies including the United States Food and Drug Administration and the European Medicines Agency, and provoked debate among investigators at institutions like Harvard Medical School, Johns Hopkins University, and Mayo Clinic. The study’s design, results, and aftermath intersect with landmark trials and figures in critical care such as PROCESS trial, PRISM study, Richard Peto, Paul Marshall (physician), and regulatory actions reviewed by panels at National Institutes of Health meetings.

Background

The rationale for the trial derived from pathophysiology studies at centers including Massachusetts General Hospital and Imperial College London, and from preclinical work by biotechnology teams in the United Kingdom and the United States. Drotrecogin alfa, a recombinant form of activated protein C previously characterized in biochemical studies at institutions like University College London and Stanford University School of Medicine, showed antithrombotic and anti-inflammatory properties in laboratory models developed by researchers affiliated with Cambridge Biomedical Campus and the Karolinska Institute. The sponsor, Eli Lilly and Company, collaborated with investigators from international networks such as the European Society of Intensive Care Medicine and the American Thoracic Society to design a trial intended to demonstrate mortality benefit in severe sepsis, a condition treated across units including those at Cleveland Clinic and Mount Sinai Hospital.

Study Design and Methods

PROWESS was a randomized, double-blind, placebo-controlled trial enrolling adults at academic and community centers including Oxford University Hospitals, University of Pennsylvania Health System, Toronto General Hospital, and Royal Melbourne Hospital. Stratification, randomization, and interim monitoring were overseen by independent committees using statistical principles referenced in texts by Bradford Hill and shaped by guidance from panels at the World Health Organization. Eligibility criteria referenced established scoring systems developed by groups at Intensive Care National Audit & Research Centre and used measures like the Acute Physiology and Chronic Health Evaluation score and organ dysfunction criteria informed by research from Vanderbilt University Medical Center. The primary endpoint was 28-day all-cause mortality, analyzed with intention-to-treat methods and subgroup analyses including cohorts defined by septic shock and organ failure, following methodologies similar to other landmark trials at Cleveland Clinic Foundation and Guy's and St Thomas' NHS Foundation Trust.

Results

Published in 2001 in a major clinical journal, the trial reported an absolute reduction in 28-day mortality favoring drotrecogin alfa in the overall cohort, with more pronounced effects in predefined high-risk subgroups such as patients with multiple organ dysfunction or high severity scores. The findings were compared and contrasted with contemporaneous critical care studies from centers like Beth Israel Deaconess Medical Center, University of California, San Francisco, and Karolinska Universitetssjukhuset. Secondary analyses and pooled datasets involving collaborators from Royal Free Hospital and Hôpital Cochin probed effects on subgroups defined by source of infection (for example cohorts treated at Hospital das Clínicas da Faculdade de Medicina da USP), comorbidities characterized in registries by Duke University Medical Center, and concomitant interventions common at Stanford Health Care. The reported mortality benefit prompted rapid inclusion in consensus statements by societies including European Society of Anaesthesiology.

Safety and Adverse Events

Safety data reported increased rates of serious bleeding events, a signal discussed in the context of hemostasis research from laboratories at McMaster University and University of Toronto. Adverse event monitoring committees, drawing expertise from centers such as National Heart, Lung, and Blood Institute–affiliated investigators and consultants formerly at GlaxoSmithKline, evaluated bleeding risks versus survival benefit. Case series and registries from tertiary centers including Henry Ford Health and Johns Hopkins Hospital further characterized hemorrhagic complications in patients receiving drotrecogin alfa, particularly in those with recent surgery or thrombocytopenia identified in cohorts studied at Mayo Clinic.

Regulatory Impact and Clinical Use

Following publication, regulatory agencies including the United States Food and Drug Administration approved drotrecogin alfa for severe sepsis in specified populations; professional guideline bodies such as the Surviving Sepsis Campaign issued recommendations incorporating the therapy. Uptake in intensive care units at institutions like Addenbrooke's Hospital and The Royal Infirmary of Edinburgh varied with local protocols developed by committees influenced by analyses from Cochrane Collaboration-style reviews and systematic reviewers at Johns Hopkins Bloomberg School of Public Health. Subsequent large trials—conducted at networks involving Vanderbilt University, University College London Hospitals, and Charité – Universitätsmedizin Berlin—and re-analyses prompted regulatory reassessment by the European Medicines Agency and advisory panels at the FDA.

Criticisms and Controversies

Debate around PROWESS centered on trial conduct, subgroup interpretation, and post-marketing surveillance, echoing controversies seen in other high-profile trials involving therapies appraised by panels at National Institutes of Health workshops. Critics from academic centers including Yale School of Medicine, Columbia University Irving Medical Center, and University of Chicago questioned aspects of patient selection, statistical handling of early withdrawals, and applicability to lower-risk populations treated at hospitals such as Sheffield Teaching Hospitals NHS Foundation Trust and Hospital Clínic de Barcelona. Meta-analyses led by investigators at University of Sydney and Imperial College London combined PROWESS data with subsequent trials to reassess efficacy and harm, ultimately influencing decisions by regulatory bodies and prompting reassessment in clinical guidelines authored by contributors from American College of Chest Physicians and European Society of Intensive Care Medicine. The episode remains a cautionary case discussed in curricula at Harvard T.H. Chan School of Public Health and in methodological texts on randomized trials.

Category:Clinical trials in critical care